Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
In laboratory environments, this dual-peptide complex operates synergistically on the angiogenic and cytoskeletal dynamics axes
Researched applications In the published preclinical and clinical literature the effects of AOD-9604 are documented in the following areas: Obesity , Phase 2b failure (2007), but a complementary mechanism in combination protocols Lipolysis in animal models , robustly demonstrated (Heffernan 2001, Ng 2009) Inhibition of lipogenesis , demonstrated in hepatocytes and adipocytes Osteoarthritis and cartilage regeneration , emerging Phase 1/2 data (mLuna Pharmaceuticals 2018+) Tendinopathy , preclinical models Age-related sarcopenia (cachexia) , exploratory plans Lipodystrophy , preclinical data in animal models Hyperlipidemia , secondary endpoints in Phase 2 trials Science & studies 4.1 Key publications Heffernan M., Summers R.J., Thorburn A., et al
It creates a concentration of 2.5 mg/mL where common doses land on clean, easy-to-read syringe markings
doi: 10.1016/j.joca.2010.08.003 130 MalemudCJ
For women going through menopause, thinning hair ranks among the most distressing physical changes, yet it remains surprisingly common
Bring vial and water to room temperature
